Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PPID | Q08752 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11190772 | 0.83 | RAB9A (0.72) | ALDH1A1LMNAPPIDPOLBHSD17B10 | |
| SCHEMBL31620937 | 0.82 | ALDH1A1 (0.60) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| Malonic Acid Diethyl Ester SCHEMBL11067701 | 0.81 | ALDH1A1 (0.57) | ALDH1A1LMNAPPIDPOLBHSD17B10 | |
| SCHEMBL21069967 | 0.80 | ALDH1A1 (0.48) | ALDH1A1LMNAPPIDPOLBHSD17B10 | |
| SCHEMBL9686760 | 0.80 | PIN1 (0.53) | ALDH1A1LMNAPPIDPOLBHSD17B10 | |
| SCHEMBL27696233 | 0.80 | NPC1 (0.52) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL10597046 | 0.79 | RAB9A (0.49) | ALDH1A1LMNAPPIDPOLBHSD17B10 | |
| SCHEMBL2224578 | 0.78 | SMN1; SMN2 (0.54) | ALDH1A1LMNAPPIDPOLBHSD17B10 | |
| SCHEMBL13977768 | 0.78 | SMN1; SMN2 (0.53) | ALDH1A1PPIDPOLBNPC1RAB9A | |
| SCHEMBL3184733 | 0.77 | ALDH1A1 (0.54) | ALDH1A1LMNAPPIDPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| CN-101626685-B | N-substituted glycine derivatives: hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2013-03-13 | — | — | CN | disclosed |
| CN-101626685-A | The glycine derivative that N-replaces: hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-01-13 | — | — | CN | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | EGLN2, EGLN3, HIF1AN | ALDH1A1 564/4885LMNA 2802/4885PPID 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.